Peripheral vascular disease (PVD) is one of several types of disturbances that can interfere with the transport of oxygen from atmospheric air in the alveoli to the ATPasecontaining inner surface of the inner mitochondria1 membrane. The consequences can include functional and structural tissue degeneration. The preferred therapeutic approach to PVD, as with any disease, is to identify and remove the cause. When this approach is not feasible, the therapist seeks to influence any aspect of the mechanism that may alleviate the damage to function and structure.The rational classical approaches to the ischemia of PVD include widening vascular channels by the surgical or medical removal of obstructing materials, vasodilation, and neovascularization. More recently, effective therapeutic agents have been developed on the basis of pathophysiologic mechanisms that do not involve an increase in the total cross-sectional area of the lumen of the vessels involved. These include drug-enhanced red cell deformability (35) and hemodilution (12) to reduce blood viscosity as a means of increasing blood flow without widening narrowed vascular channels, the trapping of free radicals that form on reperfusion of ischemic tissue (13), and better survival of injured cells by controlling the intracellular calcium ion concentration with drugs that act on calcium channel receptors (31). This discussion will deal with still another hypothesis not directly concerned with vascular channel caliber, i.e., oxygen diffusion. Impaired oxygen diffusion as a possible contributing factor to the inadequate delivery of oxygen from alveolus to mitochondria has received little attention even though limitations to oxygen diffusion are recognized (25). While good experimental data support the commonly accepted thesis that the rate of diffusion is not a limiting factor in the normal chain of oxygen transport (4), recent observations suggest the possibility that limitations of oxygen diffusion may in fact contribute significantly to the consequences of PVD,